---

JAK inhibitors: Evolving therapies in rheumatoid arthritis

Full Text PDF

---

Review Article

Author Details : Shiva Shankar Jha*

Volume : 4, Issue : 2, Year : 2018

Article Page : 43-46

https://doi.org/10.18231/2455-6777.2018.0011

Suggest article by email

Get Permission

Abstract

In rheumatoid arthritis, there has been a paradigm shift from controlling symptoms to controlling the disease progress with abrogation of inflammation. Achieving this remission or very low disease activity has become increasingly possible with USA FDA approved first JAK inhibitor, Tofacitinib in November 2012 (not in Europe). This new small molecule JAK inhibitors are oral drug working intra-cellularly in comparison to TNF? inhibitors targeting a singly cytokine within extra-cellular space confining themselves to cell surface receptors. The second JAK inhibitor Baracitinib approved in Europe in February 2017 and in USA in May 2018 has greater promises. Once daily 2 mg oral dose used either as monotherapy or in combination with methotrexate in moderate to severe active rheumatoid arthritis in adults have provided remission, even in patients who have responded inadequately or are intolerant to one or more DMARDs / bDMARDs. It is a safe second line therapy after methotrexate. In DMARD naïve patients, it is likely to become first-line agents

Keywords: JAK inhibitor, TNF? inhibitor, NSAID, bDMARD, Methotrexate, Tofacitinib.

How to cite : Jha S S , JAK inhibitors: Evolving therapies in rheumatoid arthritis. IP Int J Orthop Rheumatol 2018;4(2):43-46

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution 4.0 International License, which allows others to remix, and build upon the work, the licensor cannot revoke these freedoms as long as you follow the license terms.